Target intelligence / Profile preview

Usher syndrome type 2A pre-messenger RNA (USH2A pre-mRNA) (USH2A pre-mRNA)

Target
USH2A pre-mRNA
Molecular classification
RNA, Other
01

Overview

Usher syndrome type 2A pre-messenger RNA (USH2A pre-mRNA) is the transcript of the USH2A gene, which encodes the usherin protein. Usherin is an essential transmembrane component of the basement membrane in the inner ear and retina, playing a critical role in the maintenance of photoreceptor cells and the development of cochlear hair cell stereocilia [1, 4]. Mutations in the USH2A pre-mRNA, particularly those involving exon 13, often lead to the production of a truncated or non-functional protein, causing Usher syndrome type 2A (characterized by congenital hearing loss and progressive retinitis pigmentosa) or nonsyndromic retinitis pigmentosa [1, 2, 5]. This pre-mRNA is a significant therapeutic target for antisense oligonucleotides (ASOs), which are designed to modulate splicing [7, 9]. Because the USH2A gene is too large for conventional viral-mediated gene therapy, ASOs like ultevursen target the pre-mRNA to induce exon skipping [3, 6]. By masking specific sequences in exon 13, these drugs allow the cellular machinery to bypass the mutation-bearing exon and restore the open reading frame. This results in the synthesis of a shortened but functional usherin protein, which aims to preserve retinal function and slow the progression of vision loss in affected individuals [7, 10, 16].

Other names
Usherin pre-messenger RNAUSH2A pre-messenger RNAUsherin pre-mRNAUSH2A precursor mRNA
02

Mechanism of action

Antisense oligonucleotide-mediated exon skipping to restore the open reading frame and produce a functional, shortened usherin protein [3, 7].

03

Biological functions

mRNA splicingProtein translationVisual perceptionAuditory perceptionCellular homeostasis
04

Disease associations

Usher syndrome type 2ARetinitis pigmentosa 39
05

Safety considerations

Cataract developmentIntravitreal injection-related risks (e.g., endophthalmitis, retinal detachment, vitreous hemorrhage) [18]Off-target effects (though minimized by sequence design) [10]Need for repeated administration due to the transient nature of antisense effects [21]
06

Interacting drugs

Ultevursen (QR-421a)

1 more in the full profile.

07

Biomarkers

USH2A exon 13 mutation status (e.g., c.2299delG variant)Best-corrected visual acuity (BCVA)Retinal sensitivity (Static perimetry)Ellipsoid zone (EZ) area on optical coherence tomography (OCT)

Beyond the preview

Go deeper on Usher syndrome type 2A pre-messenger RNA (USH2A pre-mRNA) (USH2A pre-mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Usher syndrome type 2A pre-messenger RNA (USH2A pre-mRNA) (USH2A pre-mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call